Adam George

Non-Executive Director

Adam George.png

Adam George has nearly two decades of experience in the pharmaceuticals industry, previously serving as Chief Financial Officer for five years at GW Pharmaceuticals, a UK-based drug development company focused on using cannabinoid therapeutics for treating a range of diseases. GW Pharma was sold for $7.4 Bn to Jazz Pharmaceuticals. During his time, he oversaw the company’s initial public offering on Nasdaq and was involved in subsequent fundraising totalling over $1.4 Bn. Adam went on to serve as UK Managing Director from 2017 until December 2020, where he held joint responsibility for leading GW Pharmaceuticals’ Research and Development programmes.

Since 2018, Adam has also served as Audit Committee Chairman for clinical-stage biopharma NuCana Plc, in addition to multiple senior financial roles across both public and private companies throughout his 30-year career. Adam is a chartered accountant and holds a BSc in Biology from the University of Bristol.